Wednesday, September 03, 2025 7:06:44 PM
Unfortunately, you have been living in denial for way too long. UK approval is also not going to cut it because they won’t be able to execute commercially.
The shorts are not going to stop because they see an opportunity to make easy money. When a company takes 5 years to submit only one application to a tiny jurisdiction and that too without reimbursement evidence, it’s obvious they are not capable of executing in a reasonable time frame. And that has been evident from their 15+ year history. So you can expect more of the same even if NWBO does get UK approval sometimes in 2026.
But folks like you will come up with more excuses and victim mindset. No one has been stopping LP from going out there and sharing NWBO story at major investor meetings. Instead she prefers to dilute in pennies at increasingly lower share price from one round to next. Then she complains we don’t have the money to execute or do much. But you gotta go out there and present at JP Morgan like biotech meetings. So many opportunities like that every year.
The shorts are not going to stop because they see an opportunity to make easy money. When a company takes 5 years to submit only one application to a tiny jurisdiction and that too without reimbursement evidence, it’s obvious they are not capable of executing in a reasonable time frame. And that has been evident from their 15+ year history. So you can expect more of the same even if NWBO does get UK approval sometimes in 2026.
But folks like you will come up with more excuses and victim mindset. No one has been stopping LP from going out there and sharing NWBO story at major investor meetings. Instead she prefers to dilute in pennies at increasingly lower share price from one round to next. Then she complains we don’t have the money to execute or do much. But you gotta go out there and present at JP Morgan like biotech meetings. So many opportunities like that every year.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
